Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the efficacy of up to 8 cycles (24 weeks) of MYOCET plus cyclophosphamide and trastuzumab for 4 cycles followed by docetaxel plus trastuzumab for 4 cycles (MCH→TH) with free doxorubicin plus cyclophosphamide alone for 4 cycles followed by docetaxel plus trastuzumab for 4 cycles (AC→TH), each on day 1 of a 21-day cycle, as assessed by the proportion of patients with pathological complete response (pCR).
Critère d'inclusion
- Patients with human epidermal growth factor receptor-2 (HER2) positive stage II or III breast cancer